( NASDAQ-NMS:CRIS )

News from the debiopharm group A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Aug 27, 2012, 03:00 ET Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...


Jun 18, 2012, 03:00 ET Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases

Debiopharm Group™ (Debiopharm), a global biopharmaceutical development group that focuses on serious medical conditions and...


Jun 06, 2012, 04:00 ET Debiopharm Presented Results at the ASCO 2012 Annual Meeting - Results of Phase I Study With Debio 0932, an Oral HSP90 Inhibitor in Patients With Solid Tumours

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...


May 15, 2012, 03:00 ET Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis

Debiopharm Group™ (Debiopharm) and Vifor Pharma announce the signing of an exclusive agreement covering the distribution and...


Feb 16, 2012, 07:00 ET Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, and Debiopharm...


Nov 09, 2011, 05:07 ET Augurix Diagnostics Receives the 2011 'Debiopharm /Valais Award' for its Point-of-care Diagnostic Test for the Early Detection of Celiac Disease

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics,...


Oct 05, 2011, 04:00 ET The Japanese Cancer Association and Debiopharm Group™ Present Doctors Arakawa and Kurokawa With the 2011 'JCA-Mauvernay Award' for Their Innovative and Outstanding Research in the Field of Cancer

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics,...


Sep 08, 2011, 04:00 ET Debiopharm Group™ Presents the 'Debiopharm Group™ Life Sciences Award 2011' and two 'Junior Debiopharm Group™ Awards 2011' at the ISREC 2011 Life Sciences Symposium

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics,...


Jul 26, 2011, 03:00 ET INC Research and Debiopharm Group(TM) Announce Strategic Partnership

INC Research, LLC, a therapeutically focused contract research organisation (CRO) with a trusted process for delivering reliable results, and...


Jul 14, 2011, 04:45 ET Continuity as Debiopharm Group™ Management Moves Forward

  Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of...


May 04, 2011, 03:00 ET Debiopharm and Yale Announce an Exclusive License Agreement for the Development and Commercialization of Debio 1036, a First-in-Class Inhibitor for Autoimmune and Inflammatory Diseases

Debiopharm Group(TM) (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly...


Jan 18, 2011, 03:00 ET Diagnoplex Closes an Extension of its Series A Financing With a Substantial Investment by Debiopharm Group(TM)

Diagnoplex SA, a developer of molecular diagnostics for colon cancer and Debiopharm Group(TM) announced today that Diagnoplex has closed a series A...


Sep 02, 2010, 12:10 ET Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010

Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative...


Apr 27, 2010, 07:59 ET Debiopharm Group(TM) Starts Phase I Clinical Trial With Debio 0932

Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative...


Apr 08, 2010, 03:00 ET Debiopharm Group(TM) and Biocartis Embark on a Partnership Aiming at Enhancing Personalized Medicine

Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative...


Aug 04, 2009, 04:30 ET Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs...


May 11, 2009, 06:51 ET Debiopharm and Mepha Sign Distribution Agreement for Pamorelin(R) LA

- 1- 3- and 6-Month Formulations - A new Treatment for Prostate Cancer Patients in Switzerland Debiopharm Group (Debiopharm), a global...


Apr 30, 2009, 05:05 ET Clinical Update - Debio 025 in Hepatitis C

Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions, particularly in the...


Nov 20, 2008, 04:00 ET Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway

Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and...